A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the Bladder

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 807-813

  Harland, S J ^a   Kynaston, H ^c   Grigor, K ^d   Wallace, D M ^e   Beacock, C ^f   Kockelbergh, R ^g   Clawson, S ^b   Barlow, T ^b   Parmar, M K B ^b   Griffiths, G O ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^g LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

radiotherapy; randomized controlled trials; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; STATISTICAL ANALYSIS; TELANGIECTASIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UNITED KINGDOM; URINARY FREQUENCY;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 34547659670     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.024     Document Type: Article

References (15)

1. www.cancerresearchuk.org/statistics. Accessed March 2007.
2. Harland S.J. A second look at the pT1 G3 bladder tumour. Clin Oncol (R Coll Radiol) 17 (2005) 498
3. Grigor K. Transitional carcinoma of the bladder: back to basics. Urology News 1 (1997) 11
4. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90
5. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964
6. Jenkins B.J., Nauth-Misir R.R., Martin J.E., Fowler C.G., Hope-Stone H.F., and Blandy J.P. The fate of G3pT1 bladder cancer. Br J Urol 64 (1989) 608
7. Quilty P.M., and Duncan W. Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. Br J Urol 58 (1986) 147
8. Lynch T.H., Waymont B., Dunn J.A., and Wallace D.M. Urologists' attitudes to the management of bladder cancer. Br J Urol 70 (1992) 522
9. Wolf H., and Hojgaard K. Prognostic factors in local surgical treatment of invasive bladder cancer, with special reference to the presence of urothelial dysplasia. Cancer 51 (1983) 1710
10. Jakse G., Loidl W., Seeber G., and Hofstadter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?. J Urol 137 (1987) 39
11. Sivalingam S., Probert J.L., and Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int 96 (2005) 759
12. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96
13. Badalament R.A., Herr H.W., Wong G.Y., Gnecco C., Pinsky C.M., Whitmore Jr. W.F., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5 (1987) 441
14. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124
15. Palou J., Laguna P., Millan-Rodriguez F., Hall R.R., Salvador-Bayarri J., and Vicente-Rodiguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488